Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank_resource:DB00872_DB01222_nanopub.RA0uW-UPQf5h-MKdJuYT5rSbx58SRKXXycYXh6ygLISgE#assertion>. }
Showing items 1 to 6 of
6
with 100 items per page.
- drugbank_resource:DB00872_DB01222 type drugbank_vocabulary:Drug-Drug-Interaction assertion.
- drugbank_resource:DB00872_DB01222 label "DDI between Conivaptan and Budesonide - CYP3A4 Inhibitors (Strong) may increase the serum concentration of Budesonide (Systemic, Oral Inhalation). onsider reducing the oral budesonide dose when used together with a strong CYP3A4 inhibitor. This interaction is likely less severe with orally inhaled budesonide. Any patient receiving both budesonide and a strong CYP3A4 inhibitor should be monitored closely for signs/symptoms of corticosteroid excess. [drugbank_resource:DB00872_DB01222]" assertion.
- drugbank_resource:DB00872_DB01222 identifier "drugbank_resource:DB00872_DB01222" assertion.
- drugbank_resource:DB00872_DB01222 title "DDI between Conivaptan and Budesonide - CYP3A4 Inhibitors (Strong) may increase the serum concentration of Budesonide (Systemic, Oral Inhalation). onsider reducing the oral budesonide dose when used together with a strong CYP3A4 inhibitor. This interaction is likely less severe with orally inhaled budesonide. Any patient receiving both budesonide and a strong CYP3A4 inhibitor should be monitored closely for signs/symptoms of corticosteroid excess." assertion.
- drugbank:DB01222 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00872_DB01222 assertion.
- drugbank:DB00872 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00872_DB01222 assertion.